Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis

Abstract

Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases), adalimumab group (31 cases) and secukinumab group (30 cases). The nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI) in the three groups were compared before and after 12-and 24-week treatments. Clinical effectiveness and adverse reactions were observed. Results Before the treatment, there were no significant differences in NAPSI and DLQI scores among the three groups (P>0.05). After 12 weeks of the treatment, the NAPSIs in the adalimumab and the secukinumab groups were lower than that in cyclosporin group (32.16±13.82, 32.37±10.97 vs 42.20±16.66, P0.05). There were no significant differences in adverse reactions among the three groups (P=0.784). Conclusions Cyclosporin, secukinumab and adalimumab are effective and safe for nail psoriasis. Both secukinumab and adalimumab are more effective than cyclosporin, while the efficacies of secukinumab and adalimumab are comparable.

Keywords

• nail psoriasis
• cyclosporin
• secukinumab
• adalimumab